Even as Biogen weighs strategic options for its biosimilars unit, the group is celebrating an industry first. Biogen’s version of Roche’s autoimmune drug Actemra has won FDA approval, the company said ...

The FDA has approved the first biosimilar version of the interleukin-6 (IL-6) blocker tocilizumab, to be marketed as Tofidence and with indications for rheumatoid arthritis (RA), systemic juvenile ...

FRANKFURT (Reuters) -Roche said first-half core operating profit fell 14% as the Swiss drugs and diagnostics maker was hit by a sharp decline in sales of COVID-19 products but the strong launch of a ...

BOSTON, Nov. 7 (Reuters) - Swiss drugmaker Roche Holding AG said on Wednesday that its experimental rheumatoid arthritis drug, Actemra, was effective in the second of five late-stage clinical trials.